Login Register Cart 0
Generic placeholder image

Current Nanomedicine

Editor-in-Chief

ISSN (Print): 2468-1873
ISSN (Online): 2468-1881

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Development and Characterization of Lipid Nanoparticles Loaded with Antipsychotic Drugs using Central Composite Design

Author(s): Ayushi D. Patel*, Chetna D. Modi, Vaishali T. Thakkar, Hardik B. Rana and Dipika D. Chavda

Volume 14, Issue 2, 2024

Published on: 08 November, 2023

Page: [155 - 168] Pages: 14

DOI: 10.2174/0124681873270830231101205139

Price: $65

Abstract

Background: Fluoxetine and olanzapine combination tablets are available in the market for oral administration in the treatment of depression, but fluoxetine has been shown to have a dose-related side effect due to its high oral dose and ability to undergo excessive first-pass metabolism. Olanzapine has low solubility and low bioavailability.

Objective: The objective of this study was to prepare lipid nanoparticles containing fluoxetine and olanzapine to enhance the solubility and dissolution profile of the drugs.

Methods: Lipid nanoparticles (LNs) were prepared by high-speed homogenization using the ultrasonication method. Different lipids and surfactants were used to screen out the best lipids, surfactants, and their ratio in the preparation of lipid nanoparticles. Drug and polymer compatibility was examined using FTIR and DSC studies. The formulation was optimized using the central composite design to establish functional relationship between independent variables and responses. Optimized batch was characterized using particle size, PDI, zeta potential, % EE, % CDR, and stability.

Results: Phase solubility study revealed FLX to have highest solubility in stearic acid and oleic acid, whereas OLZ showed highest solubility in Precirol ATO 5 and oleic acid. Poloxamer 188 was selected on the basis of high entrapment efficiency of the drug. In LNs, no significant interaction between drug and polymer was confirmed by DSC and FTIR. The particle size of optimized batch was found to be 411.5 nm with 0.532 PDI and - 9.24 mV zeta potential. For FLX and OLZ, the %EE and %CDR after 8h were found to be more than 90%. No significant change in %EE and %CDR of the formulation was observed after 4 weeks of storage.

Conclusion: Experimental results demonstrated excellent drug entrapment as well as controlled release behavior from optimized LNs of FLX and OLZ at reduced dosage frequency.

Keywords: Fluoxetine, olanzapine, lipid nanoparticles, CCD, high-speed homogenization, ultrasonication.

« Previous Next »
Graphical Abstract

[1]
Hanwella R, De Silva V. Diagnosis and management of depression. Ceylon Med J 2008; 53(2): 60-2.
[http://dx.doi.org/10.4038/cmj.v53i2.236] [PMID: 18678125]
[2]
Amsterdam JD, Shults J. Comparison of fluoxetine, olanzapine, and combined fluoxetine plus olanzapine initial therapy of bipolar type I and type II major depression—lack of manic induction. J Affect Disord 2005; 87(1): 121-30.
[http://dx.doi.org/10.1016/j.jad.2005.02.018] [PMID: 15923042]
[3]
Drug Bank. Fluoxetine 1965. Available From: https://go.drugbank.com/drugs/DB00472
[4]
Fluoxetine. 2023. Available From: https://en.wikipedia.org/wiki/Fluoxetine
[5]
Nishtha P, Dipal P, Patel D, Patel PNP, Patel DM. Formulation and Evaluation of Fast Disintegrating Tablets of Fluoxetine and Olanzapine. J Pharm Sci Bioscientific Res 2016; 6(5): 611-20.
[6]
Vitorino C, Silva S, Gouveia F, Bicker J, Falcão A, Fortuna A. QbD-driven development of intranasal lipid nanoparticles for depression treatment. Eur J Pharm Biopharm 2020; 153: 106-20.
[http://dx.doi.org/10.1016/j.ejpb.2020.04.011] [PMID: 32525033]
[7]
Gadhave D, Choudhury H, Kokare C. Neutropenia and leukopenia protective intranasal olanzapine-loaded lipid-based nanocarriers engineered for brain delivery. Appl Nanosci 2019; 9(2): 151-68.
[http://dx.doi.org/10.1007/s13204-018-0909-3]
[8]
Patel RB, Patel MR, Bhatt KK, Patel BG, Gaikwad RV. Evaluation of brain targeting efficiency of intranasal microemulsion containing olanzapine: Pharmacodynamic and pharmacokinetic consideration. Drug Deliv 2016; 23(1): 307-15.
[http://dx.doi.org/10.3109/10717544.2014.912694] [PMID: 24845478]
[9]
Shah SN, Shahzad W. Shabana Naz Shah, Waseem Shahzad. Manufacturing of New Formulation of Olanzepine + Fluoxetine Capsules 6mg/25mg. International Journal of Clinical Medicine Research International Journal of Clinical Medicine Research 2014; 1(5): 172-5.
[10]
Patel RB/. Formulation consideration and characterization of microemulsion drug delivery system for transnasal administration of carbamazepine. Bulletin of Faculty of Pharmacy, Cairo University 2013; 51(2): 243-53.
[11]
Aher SA, Tekade AR. Transnasal Delivery of Fluoxetine HCL to Brain for Treating Depression. Theranostics of Brain, Spine & Neural Disorders 2019; 4(2): 1-7.
[12]
Mante PK, Adomako NO, Antwi P, Kusi-Boadum NK, Osafo N. Solid-lipid nanoparticle formulation improves antiseizure action of cryptolepine. Biomed Pharmacother 2021; 137: 111354.
[http://dx.doi.org/10.1016/j.biopha.2021.111354] [PMID: 33561642]
[13]
Costa CP, Moreira JN, Sousa Lobo JM, Silva AC. Intranasal delivery of nanostructured lipid carriers, solid lipid nanoparticles and nanoemulsions: A current overview of in vivo studies. Acta Pharm Sin B 2021; 11(4): 925-40.
[http://dx.doi.org/10.1016/j.apsb.2021.02.012] [PMID: 33996407]
[14]
Fahmy UA, Ahmed OAA, Badr-Eldin SM, et al. Optimized nanostructured lipid carriers integrated into in situ nasal gel for enhancing brain delivery of flibanserin. Int J Nanomedicine 2020; 15: 5253-64.
[http://dx.doi.org/10.2147/IJN.S258791] [PMID: 32801690]
[15]
Tapia-Hernández JA, Rodríguez-Felix F, Juárez-Onofre JE, et al. Zein-polysaccharide nanoparticles as matrices for antioxidant compounds: A strategy for prevention of chronic degenerative diseases. Food Res Int 2018; 111: 451-71.
[http://dx.doi.org/10.1016/j.foodres.2018.05.036] [PMID: 30007708]
[16]
Cunha S, Amaral MH, Lobo JMS, Silva AC. Lipid Nanoparticles for Nasal/Intranasal Drug Delivery. Crit Rev Ther Drug Carrier Syst 2017; 34(3): 257-82.
[http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2017018693] [PMID: 28845761]
[17]
Schubert MA, Müller-Goymann CC. Characterisation of surface-modified solid lipid nanoparticles (SLN): Influence of lecithin and nonionic emulsifier. Eur J Pharm Biopharm 2005; 61(1-2): 77-86.
[http://dx.doi.org/10.1016/j.ejpb.2005.03.006] [PMID: 16011893]
[18]
Gomaa E, Fathi HA, Eissa NG, Elsabahy M. Methods for preparation of nanostructured lipid carriers. Methods 2022; 199: 3-8.
[http://dx.doi.org/10.1016/j.ymeth.2021.05.003] [PMID: 33992771]
[19]
Yasir M, Vir Singh Sara U, Som I, Gaur P, Singh M, Ameeduzzafar. . Nose to Brain Drug Delivery: A Novel Approach Through Solid Lipid Nanoparticles. Curr Nanomed 2016; 6(2): 105-32.
[http://dx.doi.org/10.2174/2468187306666160603120318]
[20]
Tapia-Hernández JA, Torres-Chávez PI, Ramírez-Wong B, et al. Micro- and nanoparticles by electrospray: Advances and applications in foods. J Agric Food Chem 2015; 63(19): 4699-707.
[http://dx.doi.org/10.1021/acs.jafc.5b01403] [PMID: 25938374]
[21]
Wavikar PR, Vavia PR. Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery. J Liposome Res 2015; 25(2): 141-9.
[22]
Rodríguez-Félix F, Del-Toro-Sánchez CL, Javier Cinco-Moroyoqui F, et al. Preparation and Characterization of Quercetin-Loaded Zein Nanoparticles by Electrospraying and Study of In Vitro Bioavailability. J Food Sci 2019; 84(10): 2883-97.
[http://dx.doi.org/10.1111/1750-3841.14803] [PMID: 31553062]
[23]
Bhalekar M, Upadhaya P, Madgulkar A. Formulation and characterization of solid lipid nanoparticles for an anti-retroviral drug darunavir. Appl Nanosci 2017; 7(1-2): 47-57.
[http://dx.doi.org/10.1007/s13204-017-0547-1]
[24]
Tapia-Hernández JA, Del-Toro-Sánchez CL, Cinco-Moroyoqui FJ, et al. Gallic Acid-Loaded Zein Nanoparticles by Electrospraying Process. J Food Sci 2019; 84(4): 818-31.
[http://dx.doi.org/10.1111/1750-3841.14486] [PMID: 30802954]
[25]
Tapia-Hernández JA, Del-Toro-Sánchez CL, Cinco-Moroyoqui FJ, et al. Prolamins from cereal by-products: Classification, extraction, characterization and its applications in micro- and nanofabrication. Trends Food Sci Technol 2019; 90: 111-32.
[http://dx.doi.org/10.1016/j.tifs.2019.06.005]
[26]
Jaiswal P, Gidwani B, Vyas A. Nanostructured lipid carriers and their current application in targeted drug delivery. Artif Cells Nanomed Biotechnol 2016; 44(1): 27-40.
[http://dx.doi.org/10.3109/21691401.2014.909822] [PMID: 24813223]
[27]
Cunha S, Costa CP, Moreira JN, Lobo JMS, Silva AC. Journal Pre. Nanomedicine (Lond) 2020; 2020: 102206.
[http://dx.doi.org/10.1016/j.nano.2020.102206]
[28]
Beg S, Swain S, Rahman M, Hasnain MS, Imam SS. Application of Design of Experiments (DoE. Pharmaceutical Quality by Design: Principles and Applications. Amsterdam: Elsevier 2019; pp. 43-64.
[http://dx.doi.org/10.1016/B978-0-12-815799-2.00003-4]
[29]
Chettupalli AK. Design, Formulation, In-Vitro and Ex-Vivo Evaluation of Atazanavir Loaded Cubosomal Gel. Biointerface Res Appl Chem 2021; 11(4): 12037-54.
[30]
Patel S, Chavhan S, Soni H, et al. Brain targeting of risperidone-loaded solid lipid nanoparticles by intranasal route. J Drug Target 2011; 19(6): 468-74.
[http://dx.doi.org/10.3109/1061186X.2010.523787 ] [PMID: 20958095]
[31]
Mohd Y, Chauhan I, Gaur PK. Solid lipid nanoparticles for nose to brain delivery of donepezil: Formulation, optimization by Box–Behnken design, in vitro and in vivo evaluation. Artif Cells Nanomed Biotechnol 2018; 46(8): 1838-51.
[32]
Daswadkar SC, Atole AV. Formulation and Evaluation of Solid Lipid Nanoparticles of Olanzapine for the Treatment of Psychosis. J Drug Deliv Ther 2020; 10(5-s): 25-31.
[http://dx.doi.org/10.22270/jddt.v10i5-s.4440]
[33]
Abdellatif MM, Khalil IA, Khalil MAF. Sertaconazole nitrate loaded nanovesicular systems for targeting skin fungal infection: In-vitro, ex-vivo and in-vivo evaluation. Int J Pharm 2017; 527(1-2): 1-11.
[http://dx.doi.org/10.1016/j.ijpharm.2017.05.029] [PMID: 28522423]
[34]
Yasir M, Chauhan I, Zafar A, et al. Buspirone loaded solid lipid nanoparticles for amplification of nose to brain efficacy: Formulation development, optimization by Box-Behnken design, in-vitro characterization and in-vivo biological evaluation. J Drug Deliv Sci Technol 2021; 61: 102164.
[http://dx.doi.org/10.1016/j.jddst.2020.102164]
[35]
Natarajan J, Baskaran M, Humtsoe LC, Vadivelan R, Justin A. Enhanced brain targeting efficacy of Olanzapine through solid lipid nanoparticles. Artif Cells Nanomed Biotechnol 2017; 45(2): 364-71.
[http://dx.doi.org/10.3109/21691401.2016.1160402 ] [PMID: 27002542]
[36]
Youssef NAHA, Kassem AA, Farid RM, Ismail FA. EL-Massik MAE, Boraie NA. A novel nasal almotriptan loaded solid lipid nanoparticles in mucoadhesive in situ gel formulation for brain targeting: Preparation, characterization and in vivo evaluation. Int J Pharm 2018; 548(1): 609-24.
[http://dx.doi.org/10.1016/j.ijpharm.2018.07.014] [PMID: 30033394]
[37]
Prajapati JB, Patel GC. Nose to brain delivery of Rotigotine loaded solid lipid nanoparticles: Quality by design based optimization and characterization. J Drug Deliv Sci Technol 2021; 63: 102377.
[http://dx.doi.org/10.1016/j.jddst.2021.102377]
[38]
Akbari J, Saeedi M, Ahmadi F, et al. Solid lipid nanoparticles and nanostructured lipid carriers: A review of the methods of manufacture and routes of administration. Pharm Dev Technol 2022; 27(5): 525-44.
[http://dx.doi.org/10.1080/10837450.2022.2084554 ] [PMID: 35635506]
[39]
Gupta S, Kesarla R, Chotai N, Misra A, Omri A. Systematic approach for the formulation and optimization of solid lipid nanoparticles of efavirenz by high pressure homogenization using design of experiments for brain targeting and enhanced bioavailability. BioMed Res Int 2017; 2017: 1-18.
[http://dx.doi.org/10.1155/2017/5984014] [PMID: 28243600]
[40]
Patel HP, Gandhi PA, Chaudhari PS, et al. Clozapine loaded nanostructured lipid carriers engineered for brain targeting via nose-to-brain delivery: Optimization and in vivo pharmacokinetic studies. J Drug Deliv Sci Technol 2021; 64: 102533.
[http://dx.doi.org/10.1016/j.jddst.2021.102533]
[41]
Dhawan S, Kapil R, Singh B. Formulation development and systematic optimization of solid lipid nanoparticles of quercetin for improved brain delivery. J Pharm Pharmacol 2011; 63(3): 342-51.
[http://dx.doi.org/10.1111/j.2042-7158.2010.01225.x ] [PMID: 21749381]
[42]
Fatouh A, Elshafeey A, Abdelbary A. Intranasal agomelatine solid lipid nanoparticles to enhance brain delivery: Formulation, optimization and in vivo pharmacokinetics. Drug Des Devel Ther 2017; 11: 1815-25.
[http://dx.doi.org/10.2147/DDDT.S102500] [PMID: 28684900]
[43]
Abedi Gaballu F, Abbaspour-Ravasjani S, Mansoori B, et al. Comparative of in-vitro evaluation between erlotinib loaded nanostructured lipid carriers and liposomes against A549 lung cancer cell line. Iran J Pharm Res 2019; 18(3): 1168-79.
[PMID: 32641930]
[44]
Mandal A, Das V, Ghosh P, Ghosh S. Anti-diabetic effect of friedelantriterpenoids in streptozotocin induced diabetic rat. Nat Prod Commun 2015; 10(10): 1934578X1501001.
[http://dx.doi.org/10.1177/1934578X1501001013] [PMID: 26669102]
[45]
Shah P, Chavda K, Vyas B, Patel S. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: Role of P-gp inhibition. Drug Deliv Transl Res 2021; 11(3): 1166-85.
[http://dx.doi.org/10.1007/s13346-020-00839-9] [PMID: 32804301]
[46]
Kunal Jain SS. Optimization of artemether-loaded NLC for intranasal delivery using central composite design. Drug Deliv 2014; 22(7): 940-54.
[http://dx.doi.org/10.3109/10717544.2014.885999]
[47]
Emami J, Mohiti H, Hamishehkar H, Varshosaz J. Formulation and optimization of solid lipid nanoparticle formulation for pulmonary delivery of budesonide using Taguchi and Box-Behnken design. Res Pharm Sci 2015; 10(1): 17-33.
[PMID: 26430454]
[48]
Masjedi M, Azadi A, Heidari R, Mohammadi-Samani S. Nose-to-brain delivery of sumatriptan-loaded nanostructured lipid carriers: Preparation, optimization, characterization and pharmacokinetic evaluation. J Pharm Pharmacol 2020; 72(10): 1341-51.
[http://dx.doi.org/10.1111/jphp.13316] [PMID: 32579251]
[49]
Madane RG, Mahajan HS. Curcumin-loaded nanostructured lipid carriers (NLCs) for nasal administration: Design, characterization, and in vivo study. Drug Deliv 2016; 23(4): 1326-34.
[http://dx.doi.org/10.3109/10717544.2014.975382] [PMID: 25367836]
[50]
Alam T, Pandit J, Vohora D, Aqil M, Ali A, Sultana Y. Optimization of nanostructured lipid carriers of lamotrigine for brain delivery: In vitro characterization and in vivo efficacy in epilepsy. Expert Opin Drug Deliv 2015; 12(2): 181-94.
[http://dx.doi.org/10.1517/17425247.2014.945416] [PMID: 25164097]
[51]
Dange S, Kamble M, Bhalerao K, et al. Formulation and evaluation of venlafaxine nanostructured lipid carriers. J Bionanosci 2014; 8(2): 81-9.
[http://dx.doi.org/10.1166/jbns.2014.1209]
[52]
Yasir M, Sara UVS, Sara S. Solid lipid nanoparticles for nose to brain delivery of haloperidol: In vitro drug release and pharmacokinetics evaluation. Acta Pharm Sin B 2014; 4(6): 454-63.
[http://dx.doi.org/10.1016/j.apsb.2014.10.005] [PMID: 26579417]
[53]
Duangjit S, Opanasopit P, Rojanarata T, Ngawhirunpat T. Characterization and In Vitro Skin Permeation of Meloxicam-Loaded Liposomes versus Transfersomes. J Drug Deliv 2011; 2011: 1-9.
[http://dx.doi.org/10.1155/2011/418316] [PMID: 21490750]
[54]
Seedher N, Kanojia M. Co-solvent solubilization of some poorly-soluble antidiabetic drugs. Pharm Dev Technol 2009; 14(2): 185-92.
[http://dx.doi.org/10.1080/10837450802498894] [PMID: 19519190]
[55]
Dalençon F, Amjaud Y, Lafforgue C, Derouin F, Fessi H. Atovaquone and rifabutine-loaded nanocapsules: Formulation studies. Int J Pharm 1997; 153(1): 127-30.
[http://dx.doi.org/10.1016/S0378-5173(97)00076-8]
[56]
Ammar HO, Ghorab MM, Mahmoud AA, Higazy IM. Lamotrigine loaded poly-ɛ-(d,l-lactide-co-caprolactone) nanoparticles as brain delivery system. Eur J Pharm Sci 2018; 115: 77-87.
[http://dx.doi.org/10.1016/j.ejps.2018.01.028] [PMID: 29341900]
[57]
Veni DK, Gupta NV. Development and evaluation of Eudragit coated environmental sensitive solid lipid nanoparticles using central composite design module for enhancement of oral bioavailability of linagliptin. Int JPolymeric Mater Polymeric Biomater 2019; 0(0): 1-12.
[58]
Sawant K, Dodiya S. Recent advances and patents on solid lipid nanoparticles. Recent Pat Drug Deliv Formul 2008; 2(2): 120-35.
[http://dx.doi.org/10.2174/187221108784534081] [PMID: 19075903]
[59]
Kedar U, Phutane P, Shidhaye S, Kadam V. Advances in polymeric micelles for drug delivery and tumor targeting. Nanomedicine 2010; 6(6): 714-29.
[http://dx.doi.org/10.1016/j.nano.2010.05.005] [PMID: 20542144]

Rights & Permissions Print Cite
Article Metrics
16
2
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy